A decision-ready blueprint
A Search and Generative programme designed around the commercial realities of life science vc & investment firms.
Scientific, commercial, and digital architecture, with specialist expertise assembled where the engagement requires it.
Investment teams and portfolio leaders need high-science assets to be discoverable and accurately understood when potential partners, acquirers, and investors conduct initial market research. Search and Generative Engine Optimization creates the evidence and content architecture that supports a clearer, more credible public representation of those assets.
Lonrú Consulting designs S/GEO programmes around the portfolio questions that matter to a fund and its companies. The work brings together approved scientific, clinical, commercial, and market material, then creates a governed route for presenting it, reviewing it, and measuring where external discovery needs strengthening.
We define the approved portfolio, company, scientific, clinical, commercial, and published sources relevant to the selected discovery or value-creation question.
Configured systems analyse approved evidence, identify information gaps and priority questions, and prepare structured content or comparative material for review.
Lonrú provides principal-led strategy and review governance. Fund, portfolio-company, scientific, legal, and commercial owners review material within their own decision rights.
The programme is delivered through a practical evidence, content, and measurement view that helps teams assess visibility, market questions, and the next priority for an asset or portfolio.
Structure approved scientific and commercial evidence so an asset's value proposition can be found and assessed with the relevant source context intact.
Relate publications, clinical information, corporate material, and market context without presenting confidential diligence conclusions as public fact.
Provide a practical view of where priority assets have a strong public evidence base, where information gaps exist, and where content investment should be focused.
Define the role, source boundaries, and review process for each company so public representation remains accurate without blurring ownership or confidentiality.
The programme improves the evidence and clarity available to third-party discovery systems. It does not make investment recommendations, disclose confidential diligence material, or guarantee a valuation, ranking, or transaction outcome.
We establish which information can be used for public representation, who reviews it, and how the programme relates to the fund's and portfolio company's own governance before work begins.
Relevant experience
Search and generative
Establish a practical measurement system for how a company, therapy, or evidence base appears in traditional search, AI Overviews, and relevant LLM-led discovery journeys. Track the questions, sources, pages, and signals shaping that visibility, then use the findings to improve content, evidence structure, and commercial relevance.
Up to 9.2%
Engineered an AI-powered Portfolio Risk Engine to automate contract-term extraction. It identifies unlimited-liability clauses and simulates inflation impacts, reducing contract cycle time and helping prevent value leakage of up to 9.2% of annual contract value.
Architecture in context
Diagram summary: Approved portfolio evidence is contextualised, analysed, and tested through ActiveArchitecture™ before it supports clearer asset discovery and value-creation priorities.
Practical questions
Next step
Bring the decision, workflow, or delivery constraint that needs a clearer operating path.
Request a focused briefing